# A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

> **NCT02399202** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** osilodrostat

## Key facts

- **NCT ID:** NCT02399202
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-06
- **Primary completion:** 2016-03-21
- **Final completion:** 2016-03-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399202, "A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02399202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*